A detailed history of Wells Fargo & Company transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 18,389 shares of FDMT stock, worth $106,840. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,389
Previous 18,245 0.79%
Holding current value
$106,840
Previous $382,000 48.17%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$10.81 - $27.22 $1,556 - $3,919
144 Added 0.79%
18,389 $198,000
Q2 2024

Aug 13, 2024

BUY
$20.93 - $30.01 $81,627 - $117,039
3,900 Added 27.19%
18,245 $382,000
Q1 2024

May 10, 2024

BUY
$17.03 - $35.87 $35,269 - $74,286
2,071 Added 16.87%
14,345 $457,000
Q4 2023

Feb 09, 2024

SELL
$9.76 - $21.25 $193,452 - $421,196
-19,821 Reduced 61.76%
12,274 $248,000
Q3 2023

Nov 13, 2023

SELL
$12.64 - $19.76 $88,328 - $138,082
-6,988 Reduced 17.88%
32,095 $408,000
Q2 2023

Aug 15, 2023

BUY
$15.16 - $23.26 $168,200 - $258,069
11,095 Added 39.64%
39,083 $706,000
Q1 2023

May 12, 2023

BUY
$15.45 - $23.19 $429,324 - $644,403
27,788 Added 13894.0%
27,988 $481,000
Q4 2022

Feb 13, 2023

SELL
$6.85 - $25.46 $472 - $1,756
-69 Reduced 25.65%
200 $4,000
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.48 $1,941 - $3,202
-279 Reduced 50.91%
269 $3,000
Q2 2022

Aug 12, 2022

SELL
$5.68 - $15.99 $59,816 - $168,390
-10,531 Reduced 95.05%
548 $3,000
Q1 2022

May 16, 2022

SELL
$13.16 - $22.64 $120,479 - $207,269
-9,155 Reduced 45.25%
11,079 $168,000
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $245,477 - $413,397
12,550 Added 163.33%
20,234 $444,000
Q3 2021

Nov 15, 2021

BUY
$22.73 - $36.04 $155,905 - $247,198
6,859 Added 831.39%
7,684 $206,000
Q2 2021

Aug 16, 2021

SELL
$22.2 - $42.29 $35,853 - $68,298
-1,615 Reduced 66.19%
825 $20,000
Q1 2021

May 13, 2021

BUY
$35.94 - $52.67 $87,693 - $128,514
2,440 New
2,440 $106,000

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $188M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.